US20090162359A1
(en)
|
2007-12-21 |
2009-06-25 |
Christian Klein |
Bivalent, bispecific antibodies
|
US9266967B2
(en)
|
2007-12-21 |
2016-02-23 |
Hoffmann-La Roche, Inc. |
Bivalent, bispecific antibodies
|
WO2010112193A1
(en)
|
2009-04-02 |
2010-10-07 |
Roche Glycart Ag |
Multispecific antibodies comprising full length antibodies and single chain fab fragments
|
JP5616428B2
(ja)
|
2009-04-07 |
2014-10-29 |
ロシュ グリクアート アクチェンゲゼルシャフト |
三価の二重特異性抗体
|
US9676845B2
(en)
|
2009-06-16 |
2017-06-13 |
Hoffmann-La Roche, Inc. |
Bispecific antigen binding proteins
|
US8703132B2
(en)
*
|
2009-06-18 |
2014-04-22 |
Hoffmann-La Roche, Inc. |
Bispecific, tetravalent antigen binding proteins
|
WO2011028952A1
(en)
|
2009-09-02 |
2011-03-10 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
AU2010296018B2
(en)
|
2009-09-16 |
2016-05-05 |
Genentech, Inc. |
Coiled coil and/or tether containing protein complexes and uses thereof
|
TW201138821A
(en)
|
2010-03-26 |
2011-11-16 |
Roche Glycart Ag |
Bispecific antibodies
|
CN105585630B
(zh)
|
2010-07-29 |
2020-09-15 |
Xencor公司 |
具有修改的等电点的抗体
|
RU2013110875A
(ru)
|
2010-08-24 |
2014-09-27 |
Ф.Хоффманн-Ля Рош Аг |
БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА, СОДЕРЖАЩИЕ СТАБИЛИЗИРОВАННЫЙ ДИСУЛЬФИДОМ ФРАГМЕНТ Fv
|
PL2635607T3
(pl)
|
2010-11-05 |
2020-05-18 |
Zymeworks Inc. |
Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC
|
TWI807362B
(zh)
|
2010-11-30 |
2023-07-01 |
日商中外製藥股份有限公司 |
細胞傷害誘導治療劑
|
SG191153A1
(en)
|
2010-12-23 |
2013-07-31 |
Hoffmann La Roche |
Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
|
KR101638224B1
(ko)
|
2011-02-28 |
2016-07-08 |
에프. 호프만-라 로슈 아게 |
항원 결합 단백질
|
CN103403025B
(zh)
|
2011-02-28 |
2016-10-12 |
弗·哈夫曼-拉罗切有限公司 |
单价抗原结合蛋白
|
WO2012116453A1
(en)
|
2011-03-03 |
2012-09-07 |
Zymeworks Inc. |
Multivalent heteromultimer scaffold design and constructs
|
EP2699596A4
(en)
|
2011-04-22 |
2015-01-14 |
Emergent Product Dev Seattle |
PROSTATE-SPECIFIC MEMBRANE ANTIGEN-BINDING PROTEINS AND RELATED COMPOSITIONS AND METHODS
|
EA201892619A1
(ru)
|
2011-04-29 |
2019-04-30 |
Роше Гликарт Аг |
Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
|
RU2605390C2
(ru)
|
2011-08-23 |
2016-12-20 |
Рош Гликарт Аг |
Биспецифические антитела, специфичные к антигенам, активирующим т-клетки, и опухолевому антигену, и способы их применения
|
JP2014534806A
(ja)
|
2011-08-23 |
2014-12-25 |
ロシュ グリクアート アーゲー |
抗mcsp抗体
|
PL2748201T3
(pl)
*
|
2011-08-23 |
2018-04-30 |
Roche Glycart Ag |
Aktywujące komórki t dwuswoiste cząsteczki wiążące antygen
|
US10851178B2
(en)
|
2011-10-10 |
2020-12-01 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
WO2013063702A1
(en)
|
2011-11-04 |
2013-05-10 |
Zymeworks Inc. |
Stable heterodimeric antibody design with mutations in the fc domain
|
KR20140127854A
(ko)
|
2012-02-10 |
2014-11-04 |
제넨테크, 인크. |
단일-쇄 항체 및 다른 이종다량체
|
WO2013187495A1
(ja)
|
2012-06-14 |
2013-12-19 |
中外製薬株式会社 |
改変されたFc領域を含む抗原結合分子
|
US9499634B2
(en)
|
2012-06-25 |
2016-11-22 |
Zymeworks Inc. |
Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
|
WO2014001325A1
(en)
|
2012-06-27 |
2014-01-03 |
F. Hoffmann-La Roche Ag |
Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
|
EP2867253B1
(en)
|
2012-06-27 |
2016-09-14 |
F. Hoffmann-La Roche AG |
Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof
|
JP6498601B2
(ja)
|
2012-07-13 |
2019-04-10 |
ザイムワークス,インコーポレイテッド |
多価ヘテロ多量体足場設計および構築物
|
US9682143B2
(en)
*
|
2012-08-14 |
2017-06-20 |
Ibc Pharmaceuticals, Inc. |
Combination therapy for inducing immune response to disease
|
WO2014028560A2
(en)
*
|
2012-08-14 |
2014-02-20 |
Ibc Pharmaceuticals, Inc. |
T-cell redirecting bispecific antibodies for treatment of disease
|
CA2879768A1
(en)
|
2012-10-08 |
2014-04-17 |
Roche Glycart Ag |
Fc-free antibodies comprising two fab-fragments and methods of use
|
JP6571527B2
(ja)
|
2012-11-21 |
2019-09-04 |
ウーハン ワイゼットワイ バイオファルマ カンパニー リミテッドWuhan Yzy Biopharma Co., Ltd. |
二重特異性抗体
|
CA3206122A1
(en)
|
2012-11-28 |
2014-06-05 |
Zymeworks Bc Inc. |
Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
|
US9914785B2
(en)
|
2012-11-28 |
2018-03-13 |
Zymeworks Inc. |
Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
US10487155B2
(en)
|
2013-01-14 |
2019-11-26 |
Xencor, Inc. |
Heterodimeric proteins
|
KR102211837B1
(ko)
|
2013-01-14 |
2021-02-03 |
젠코어 인코포레이티드 |
신규한 이형이량체 단백질
|
US11053316B2
(en)
|
2013-01-14 |
2021-07-06 |
Xencor, Inc. |
Optimized antibody variable regions
|
US9701759B2
(en)
|
2013-01-14 |
2017-07-11 |
Xencor, Inc. |
Heterodimeric proteins
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
US10131710B2
(en)
|
2013-01-14 |
2018-11-20 |
Xencor, Inc. |
Optimized antibody variable regions
|
CA2897987A1
(en)
|
2013-01-15 |
2014-07-24 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
US10077315B2
(en)
*
|
2013-02-05 |
2018-09-18 |
Engmab Sàrl |
Bispecific antibodies against CD3 and BCMA
|
EP3626741A1
(en)
|
2013-02-20 |
2020-03-25 |
The Trustees Of The University Of Pennsylvania |
Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
|
US20140242080A1
(en)
*
|
2013-02-26 |
2014-08-28 |
Roche Glycart Ag |
Bispecific t cell activating antigen binding molecules
|
JP6499087B2
(ja)
|
2013-02-26 |
2019-04-10 |
ロシュ グリクアート アーゲー |
二重特異性t細胞活性化抗原結合分子
|
HUE047925T2
(hu)
|
2013-02-26 |
2020-05-28 |
Roche Glycart Ag |
Bispecifikus, T-sejt-aktiváló, CD3- és CEA-specifikus antigénkötõ molekulák
|
US10106624B2
(en)
|
2013-03-15 |
2018-10-23 |
Xencor, Inc. |
Heterodimeric proteins
|
AU2014232416B2
(en)
|
2013-03-15 |
2017-09-28 |
Xencor, Inc. |
Modulation of T Cells with Bispecific Antibodies and FC Fusions
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
US10519242B2
(en)
|
2013-03-15 |
2019-12-31 |
Xencor, Inc. |
Targeting regulatory T cells with heterodimeric proteins
|
UA118028C2
(uk)
*
|
2013-04-03 |
2018-11-12 |
Рош Глікарт Аг |
Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
|
EP2789630A1
(en)
|
2013-04-09 |
2014-10-15 |
EngMab AG |
Bispecific antibodies against CD3e and ROR1
|
SG11201508911PA
(en)
*
|
2013-04-29 |
2015-11-27 |
Hoffmann La Roche |
Human fcrn-binding modified antibodies and methods of use
|
JP2016531100A
(ja)
*
|
2013-07-12 |
2016-10-06 |
ザイムワークス,インコーポレイテッド |
二重特異的なcd3及びcd19抗原結合構築物
|
CN104342453A
(zh)
*
|
2013-08-06 |
2015-02-11 |
深圳先进技术研究院 |
含基因工程抗体基因表达盒的微环dna重组母质粒、含该表达盒的微环dna及应用
|
KR20160044060A
(ko)
|
2013-10-11 |
2016-04-22 |
에프. 호프만-라 로슈 아게 |
다중특이적 도메인 교환된 통상의 가변 경쇄 항체
|
EP3372236A1
(en)
|
2013-10-25 |
2018-09-12 |
PsiOxus Therapeutics Limited |
Oncolytic adenoviruses armed with heterologous genes
|
CN105940107B
(zh)
|
2013-11-11 |
2021-06-15 |
中外制药株式会社 |
含有改变了抗体可变区的抗原结合分子
|
AU2014357292B2
(en)
|
2013-11-27 |
2020-06-25 |
Zymeworks Bc Inc. |
Bispecific antigen-binding constructs targeting HER2
|
MX2016008667A
(es)
*
|
2013-12-30 |
2017-02-02 |
Epimab Biotherapeutics Inc |
Inmunoglobulina con fab en tandem y usos de esta.
|
CA2932364A1
(en)
|
2014-01-15 |
2015-07-23 |
F. Hoffmann-La Roche Ag |
Fc-region variants with improved protein a-binding
|
RS59907B1
(sr)
|
2014-03-28 |
2020-03-31 |
Xencor Inc |
Bispecifična antitela koja se vezuju za cd38 i cd3
|
RU2722788C2
(ru)
|
2014-04-07 |
2020-06-03 |
Чугаи Сейяку Кабусики Кайся |
Иммуноактивирующая антигенсвязывающая молекула
|
CA2947157A1
(en)
*
|
2014-05-13 |
2015-11-19 |
Chugai Seiyaku Kabushiki Kaisha |
T cell-redirected antigen-binding molecule for cells having immunosuppression function
|
EP3107938B1
(en)
|
2014-05-28 |
2022-05-04 |
Zymeworks Inc. |
Modified antigen binding polypeptide constructs and uses thereof
|
EP3164417A1
(en)
|
2014-07-01 |
2017-05-10 |
Pfizer Inc. |
Bispecific heterodimeric diabodies and uses thereof
|
CA2954791A1
(en)
*
|
2014-07-14 |
2016-01-21 |
The Regents Of The University Of California |
Crispr/cas transcriptional modulation
|
EP3172237A2
(en)
|
2014-07-21 |
2017-05-31 |
Novartis AG |
Treatment of cancer using humanized anti-bcma chimeric antigen receptor
|
KR20170037625A
(ko)
|
2014-07-21 |
2017-04-04 |
노파르티스 아게 |
Cll-1 키메라 항원 수용체를 사용한 암의 치료
|
WO2016014974A2
(en)
|
2014-07-25 |
2016-01-28 |
Cytomx Therapeutics, Inc. |
Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
|
JP6749312B2
(ja)
|
2014-07-31 |
2020-09-02 |
アムゲン リサーチ (ミュンヘン) ゲーエムベーハーAMGEN Research(Munich)GmbH |
最適化された種間特異的二重特異性単鎖抗体コンストラクト
|
CA2951599A1
(en)
*
|
2014-08-04 |
2016-02-11 |
F. Hoffmann-La Roche Ag |
Bispecific t cell activating antigen binding molecules
|
EP2982692A1
(en)
*
|
2014-08-04 |
2016-02-10 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA
|
ES2887549T3
(es)
|
2014-09-03 |
2021-12-23 |
Boehringer Ingelheim Int |
Compuesto dirigido a IL-23A y TNF-alfa y usos del mismo
|
WO2016055592A1
(en)
*
|
2014-10-09 |
2016-04-14 |
Engmab Ag |
Bispecific antibodies against cd3epsilon and ror1
|
US11154615B2
(en)
|
2014-11-11 |
2021-10-26 |
Chugai Seiyaku Kabushiki Kaisha |
Library of antigen-binding molecules including modified antibody variable region
|
MX2017006610A
(es)
|
2014-11-20 |
2017-09-29 |
Hoffmann La Roche |
Terapia combinada de moleculas de union a antigeno biespecificas activadoras de celulas t y antagonistas de union de eje de pd-1.
|
MY184889A
(en)
*
|
2014-11-20 |
2021-04-29 |
Hoffmann La Roche |
T cell activating bispecific antigen binding molecules
|
AU2015353416C1
(en)
|
2014-11-26 |
2022-01-27 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and CD38
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
IL252480B2
(en)
|
2014-11-26 |
2023-12-01 |
Xencor Inc |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
ES2764111T3
(es)
|
2014-12-03 |
2020-06-02 |
Hoffmann La Roche |
Anticuerpos multiespecíficos
|
SI3227336T1
(sl)
|
2014-12-05 |
2019-10-30 |
Hoffmann La Roche |
Protitelesa proti CD79b in postopki uporabe
|
EP3233920B1
(en)
*
|
2014-12-19 |
2020-08-26 |
Alkermes, Inc. |
Single chain fc fusion proteins
|
US10428155B2
(en)
|
2014-12-22 |
2019-10-01 |
Xencor, Inc. |
Trispecific antibodies
|
JP6853176B2
(ja)
|
2015-01-08 |
2021-03-31 |
ゲンマブ エー/エス |
Cd3およびcd20に対する二重特異性抗体
|
US10227411B2
(en)
|
2015-03-05 |
2019-03-12 |
Xencor, Inc. |
Modulation of T cells with bispecific antibodies and FC fusions
|
MX2017013348A
(es)
|
2015-04-17 |
2018-08-01 |
Amgen Res Munich Gmbh |
Construcciones de anticuerpos biespecificos contra cdh3 y cd3.
|
JP6996983B2
(ja)
|
2015-06-16 |
2022-02-21 |
ジェネンテック, インコーポレイテッド |
抗cll-1抗体及び使用方法
|
EP4074730A1
(en)
|
2015-06-24 |
2022-10-19 |
F. Hoffmann-La Roche AG |
Anti-transferrin receptor antibodies with tailored affinity
|
EP3322735A4
(en)
|
2015-07-15 |
2019-03-13 |
Zymeworks Inc. |
BISPECIFIC ANTIGEN-BINDING CONSTRUCTS CONJUGATED TO A MEDICINAL PRODUCT
|
TW202346349A
(zh)
|
2015-07-31 |
2023-12-01 |
德商安美基研究(慕尼黑)公司 |
Dll3及cd3抗體構築體
|
TWI744242B
(zh)
|
2015-07-31 |
2021-11-01 |
德商安美基研究(慕尼黑)公司 |
Egfrviii及cd3抗體構築體
|
TWI796283B
(zh)
|
2015-07-31 |
2023-03-21 |
德商安美基研究(慕尼黑)公司 |
Msln及cd3抗體構築體
|
TWI717375B
(zh)
|
2015-07-31 |
2021-02-01 |
德商安美基研究(慕尼黑)公司 |
Cd70及cd3抗體構築體
|
TWI829617B
(zh)
|
2015-07-31 |
2024-01-21 |
德商安美基研究(慕尼黑)公司 |
Flt3及cd3抗體構築體
|
JO3620B1
(ar)
|
2015-08-05 |
2020-08-27 |
Amgen Res Munich Gmbh |
مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
|
UA126278C2
(uk)
|
2015-09-21 |
2022-09-14 |
Аптево Рісьорч Енд Девелопмент Ллс |
Поліпептиди, які зв'язують cd3
|
AR106188A1
(es)
|
2015-10-01 |
2017-12-20 |
Hoffmann La Roche |
Anticuerpos anti-cd19 humano humanizados y métodos de utilización
|
EP3913000A1
(en)
*
|
2015-10-02 |
2021-11-24 |
F. Hoffmann-La Roche AG |
Bispecific anti-cd19xcd3 t cell activating antigen binding molecules
|
AR106189A1
(es)
|
2015-10-02 |
2017-12-20 |
Hoffmann La Roche |
ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
|
NZ741067A
(en)
*
|
2015-10-02 |
2023-07-28 |
Hoffmann La Roche |
Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use
|
PE20180484A1
(es)
|
2015-10-02 |
2018-03-07 |
Hoffmann La Roche |
Moleculas biespecificas de union a antigeno activadoras de celulas t
|
CN108026179A
(zh)
*
|
2015-10-02 |
2018-05-11 |
豪夫迈·罗氏有限公司 |
结合间皮素和cd3的双特异性t细胞活化性抗原结合分子
|
CN116396393A
(zh)
|
2015-10-08 |
2023-07-07 |
酵活英属哥伦比亚省公司 |
包含κ和λ轻链的抗原结合多肽构建体及其用途
|
EP3378488A4
(en)
|
2015-11-18 |
2019-10-30 |
Chugai Seiyaku Kabushiki Kaisha |
METHOD FOR ENHANCING THE HUMORAL IMMUNE RESPONSE
|
WO2017086367A1
(ja)
|
2015-11-18 |
2017-05-26 |
中外製薬株式会社 |
免疫抑制機能を有する細胞に対するt細胞リダイレクト抗原結合分子を用いた併用療法
|
WO2017087789A1
(en)
*
|
2015-11-19 |
2017-05-26 |
Revitope Limited |
Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells
|
CN108699136B
(zh)
|
2015-12-07 |
2022-03-18 |
Xencor股份有限公司 |
结合cd3和psma的异二聚抗体
|
KR20180085740A
(ko)
|
2015-12-09 |
2018-07-27 |
에프. 호프만-라 로슈 아게 |
항-약물 항체의 형성을 감소시키기 위한 ii형 항-cd20 항체
|
EP3178848A1
(en)
|
2015-12-09 |
2017-06-14 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
|
KR20180097615A
(ko)
|
2016-01-08 |
2018-08-31 |
에프. 호프만-라 로슈 아게 |
Pd-1 축 결합 길항물질 및 항-cea/항-cd3 이중특이성 항체를 사용하는 cea-양성 암의 치료 방법
|
EP3405493A1
(en)
|
2016-01-22 |
2018-11-28 |
Janssen Biotech, Inc. |
Anti-ror1 antibodies, ror1 x cd3 bispecific antibodies, and methods of using the same
|
DK3411404T3
(da)
|
2016-02-03 |
2023-01-30 |
Amgen Res Munich Gmbh |
Psma- og cd3-bispecifikke t-celleinddragende antistofkonstruktioner
|
EA039859B1
(ru)
|
2016-02-03 |
2022-03-21 |
Эмджен Рисерч (Мюник) Гмбх |
Биспецифические конструкты антител, связывающие egfrviii и cd3
|
EP3411402B1
(en)
|
2016-02-03 |
2021-12-22 |
Amgen Research (Munich) GmbH |
Bcma and cd3 bispecific t cell engaging antibody constructs
|
AU2017214692B2
(en)
|
2016-02-06 |
2021-11-04 |
Epimab Biotherapeutics, Inc. |
Fabs-in-tandem immunoglobulin and uses thereof
|
BR112018068354A2
(pt)
*
|
2016-03-11 |
2019-01-15 |
Bluebird Bio Inc |
células efetoras imunológicas do genoma editado
|
CN109153728A
(zh)
|
2016-03-21 |
2019-01-04 |
埃尔斯塔治疗公司 |
多特异性和多功能分子及其用途
|
PL3433280T3
(pl)
|
2016-03-22 |
2023-07-31 |
F. Hoffmann-La Roche Ag |
Dwuswoiste cząsteczki limfocytów T aktywowane przez proteazy
|
KR102437015B1
(ko)
|
2016-04-15 |
2022-08-29 |
메모리얼 슬로안 케터링 캔서 센터 |
유전자이식 t 세포 및 키메라 항원 수용체 t 세포 조성물 및 관련 방법
|
JOP20170091B1
(ar)
|
2016-04-19 |
2021-08-17 |
Amgen Res Munich Gmbh |
إعطاء تركيبة ثنائية النوعية ترتبط بـ cd33 وcd3 للاستخدام في طريقة لعلاج اللوكيميا النخاعية
|
WO2018220099A1
(en)
*
|
2017-06-02 |
2018-12-06 |
F. Hoffmann-La Roche Ag |
Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
|
RU2767357C2
(ru)
|
2016-06-14 |
2022-03-17 |
Ксенкор, Инк. |
Биспецифические антитела-ингибиторы контрольных точек
|
AU2017291321B2
(en)
|
2016-06-22 |
2020-06-18 |
Alkermes, Inc. |
Compositions and methods for modulating IL-10 immunostimulatory and anti-inflammatory properties
|
MX2018016265A
(es)
|
2016-06-28 |
2019-07-04 |
Xencor Inc |
Anticuerpos heterodimericos que se unen al receptor 2 de somatostatina.
|
CN109476749A
(zh)
|
2016-06-30 |
2019-03-15 |
豪夫迈·罗氏有限公司 |
改良的过继性t细胞疗法
|
TWI790206B
(zh)
*
|
2016-07-18 |
2023-01-21 |
法商賽諾菲公司 |
特異性結合至cd3和cd123的雙特異性抗體樣結合蛋白
|
GB201713765D0
(en)
|
2017-08-28 |
2017-10-11 |
Psioxus Therapeutics Ltd |
Modified adenovirus
|
US10793632B2
(en)
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
JP7022123B2
(ja)
|
2016-09-30 |
2022-02-17 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
Cd3に対する二重特異性抗体
|
EP3526240A1
(en)
|
2016-10-14 |
2019-08-21 |
Xencor, Inc. |
Bispecific heterodimeric fusion proteins containing il-15/il-15ralpha fc-fusion proteins and pd-1 antibody fragments
|
JOP20190189A1
(ar)
|
2017-02-02 |
2019-08-01 |
Amgen Res Munich Gmbh |
تركيبة صيدلانية ذات درجة حموضة منخفضة تتضمن بنيات جسم مضاد يستهدف الخلية t
|
WO2018148454A1
(en)
*
|
2017-02-09 |
2018-08-16 |
The Regents Of The University Of California |
Chimeric t cell antigen receptors and methods of use thereof
|
WO2018151820A1
(en)
|
2017-02-16 |
2018-08-23 |
Elstar Therapeutics, Inc. |
Multifunctional molecules comprising a trimeric ligand and uses thereof
|
SG11201907422RA
(en)
|
2017-02-17 |
2019-09-27 |
Denali Therapeutics Inc |
Anti-tau antibodies and methods of use thereof
|
KR20190124270A
(ko)
|
2017-03-10 |
2019-11-04 |
에프. 호프만-라 로슈 아게 |
다중특이적 항체의 생산 방법
|
CR20190431A
(es)
|
2017-03-27 |
2019-11-01 |
Hoffmann La Roche |
Formatos mejorados de receptor de unión a antígeno
|
JP7029822B2
(ja)
*
|
2017-03-29 |
2022-03-04 |
タイペイ・メディカル・ユニバーシティ |
抗原特異的t細胞及びその使用
|
RU2019134462A
(ru)
|
2017-04-03 |
2021-05-05 |
Ф. Хоффманн-Ля Рош Аг |
Антитела, связывающиеся с steap-1
|
CN110402255B
(zh)
*
|
2017-04-04 |
2022-12-02 |
豪夫迈·罗氏有限公司 |
新颖的能够特异性结合cd40和fap的双特异性抗原结合分子
|
US11555056B2
(en)
|
2017-04-26 |
2023-01-17 |
Mayo Foundation for Medical Education and Research and Board of Regents |
Methods and materials for treating cancer
|
UY37726A
(es)
|
2017-05-05 |
2018-11-30 |
Amgen Inc |
Composición farmacéutica que comprende constructos de anticuerpos biespecíficos para almacenamiento y administración mejorados
|
WO2018222901A1
(en)
|
2017-05-31 |
2018-12-06 |
Elstar Therapeutics, Inc. |
Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
|
US20180371089A1
(en)
*
|
2017-06-22 |
2018-12-27 |
Development Center For Biotechnology |
Asymmetric heterodimeric fc-scfv fusion anti-globo h and anti-cd3 bispecific antibody and uses thereof in caner therapy
|
CN111132733A
(zh)
|
2017-06-30 |
2020-05-08 |
Xencor股份有限公司 |
含有IL-15/IL-15Rα和抗原结合结构域的靶向异源二聚体Fc融合蛋白
|
WO2019035938A1
(en)
|
2017-08-16 |
2019-02-21 |
Elstar Therapeutics, Inc. |
MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
|
EP3457139A1
(en)
|
2017-09-19 |
2019-03-20 |
Promise Advanced Proteomics |
Antibody-like peptides for quantifying therapeutic antibodies
|
TWI687227B
(zh)
*
|
2017-10-03 |
2020-03-11 |
生倍科技股份有限公司 |
用於t細胞免疫療法之組合及其用途
|
TW201927816A
(zh)
|
2017-10-14 |
2019-07-16 |
美商Cytomx生物製藥公司 |
抗體、可活化之抗體、雙特異性抗體、和雙特異性可活化之抗體、及其使用方法
|
WO2019079772A1
(en)
|
2017-10-20 |
2019-04-25 |
Fred Hutchinson Cancer Research Center |
SYSTEMS AND METHODS FOR GENETICALLY MODIFIED B-LYMPHOCYTES FOR EXPRESSING SELECTED ANTIBODIES
|
US10981992B2
(en)
|
2017-11-08 |
2021-04-20 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
EP3706793A1
(en)
|
2017-11-08 |
2020-09-16 |
Xencor, Inc. |
Bispecific and monospecific antibodies using novel anti-pd-1 sequences
|
JP7184894B2
(ja)
|
2017-11-27 |
2022-12-06 |
4ディー モレキュラー セラピューティクス インコーポレイテッド |
アデノ随伴ウイルス変異キャプシドおよび血管新生の阻害のための使用
|
EP3720963A4
(en)
|
2017-12-05 |
2021-12-08 |
Chugai Seiyaku Kabushiki Kaisha |
ANTIGEN BINDING MOLECULE INCLUDING A VARIABLE REGION OF MODIFIED ANTIBODIES BINDING TO CD3 AND CD137
|
MX2020006007A
(es)
|
2017-12-11 |
2020-08-17 |
Amgen Inc |
Procedimiento de fabricacion continuo para productos de anticuerpos biespecificos.
|
SG11202005732XA
(en)
|
2017-12-19 |
2020-07-29 |
Xencor Inc |
Engineered il-2 fc fusion proteins
|
TWI805665B
(zh)
|
2017-12-21 |
2023-06-21 |
瑞士商赫孚孟拉羅股份公司 |
結合hla-a2/wt1之抗體
|
CA3083579A1
(en)
|
2017-12-22 |
2019-06-27 |
Genentech, Inc. |
Targeted integration of nucleic acids
|
TW201940518A
(zh)
|
2017-12-29 |
2019-10-16 |
美商安進公司 |
針對muc17和cd3之雙特異性抗體構建體
|
EP3732193A1
(en)
|
2017-12-29 |
2020-11-04 |
Alector LLC |
Anti-tmem106b antibodies and methods of use thereof
|
EP3746470A1
(en)
|
2018-01-31 |
2020-12-09 |
F. Hoffmann-La Roche AG |
Stabilized immunoglobulin domains
|
CN111971301A
(zh)
|
2018-01-31 |
2020-11-20 |
艾莱克特有限责任公司 |
抗ms4a4a抗体及其使用方法
|
US20200354457A1
(en)
|
2018-01-31 |
2020-11-12 |
Hoffmann-La Roche Inc. |
Bispecific antibodies comprising an antigen-binding site binding to lag3
|
AU2019218959A1
(en)
|
2018-02-08 |
2020-09-03 |
Genentech, Inc. |
Bispecific antigen-binding molecules and methods of use
|
TWI829667B
(zh)
|
2018-02-09 |
2024-01-21 |
瑞士商赫孚孟拉羅股份公司 |
結合gprc5d之抗體
|
WO2019178362A1
(en)
|
2018-03-14 |
2019-09-19 |
Elstar Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
US20210009711A1
(en)
|
2018-03-14 |
2021-01-14 |
Elstar Therapeutics, Inc. |
Multifunctional molecules and uses thereof
|
TW202003839A
(zh)
|
2018-03-29 |
2020-01-16 |
美商建南德克公司 |
調節哺乳動物細胞之生乳活性
|
WO2019195623A2
(en)
|
2018-04-04 |
2019-10-10 |
Xencor, Inc. |
Heterodimeric antibodies that bind fibroblast activation protein
|
AR115052A1
(es)
|
2018-04-18 |
2020-11-25 |
Hoffmann La Roche |
Anticuerpos multiespecíficos y utilización de los mismos
|
CA3097741A1
(en)
|
2018-04-18 |
2019-10-24 |
Xencor, Inc. |
Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
|
MX2020010910A
(es)
|
2018-04-18 |
2021-02-09 |
Xencor Inc |
Proteinas de fusion heterodimericas dirigidas a pd-1 que contienen proteinas de fusion il-15 / il-15ra fc y dominios de union al antigeno pd-1 y usos de los mismos.
|
AR115418A1
(es)
|
2018-05-25 |
2021-01-13 |
Alector Llc |
ANTICUERPOS ANTI-SIRPA (PROTEÍNA REGULADORA DE SEÑALES a) Y MÉTODOS DE USO DE LOS MISMOS
|
MX2020013443A
(es)
|
2018-06-13 |
2021-02-26 |
Novartis Ag |
Receptores de antigeno quimerico de bcma y usos de los mismos.
|
SG11202010990TA
(en)
|
2018-06-29 |
2020-12-30 |
Alector Llc |
Anti-sirp-beta1 antibodies and methods of use thereof
|
CA3105448A1
(en)
|
2018-07-03 |
2020-01-09 |
Elstar Therapeutics, Inc. |
Anti-tcr antibody molecules and uses thereof
|
PE20210186A1
(es)
|
2018-07-13 |
2021-02-02 |
Alector Llc |
Anticuerpos anti-sortilina y metodos para su uso
|
JP2021532140A
(ja)
|
2018-07-30 |
2021-11-25 |
アムジェン リサーチ (ミュニック) ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Cd33及びcd3に結合する二重特異性抗体コンストラクトの長期投与
|
US20210284732A1
(en)
|
2018-07-31 |
2021-09-16 |
Amgen Research (Munich) Gmbh |
Dosing regimen for bcma-cd3 bispecific antibodies
|
CR20210120A
(es)
|
2018-08-03 |
2021-05-21 |
Amgen Inc |
Constructos de anticuerpos para cldn18.2 y cd3
|
BR112021005669A2
(pt)
|
2018-09-28 |
2021-06-22 |
Amgen Inc. |
anticorpos contra bcma solúvel
|
EP3861016A2
(en)
|
2018-10-03 |
2021-08-11 |
Xencor, Inc. |
Il-12 heterodimeric fc-fusion proteins
|
MX2021003976A
(es)
|
2018-10-11 |
2021-05-27 |
Amgen Inc |
Procesamiento posterior de constructos de anticuerpos biespecificos.
|
CA3118397A1
(en)
*
|
2018-11-01 |
2020-05-07 |
Shandong Newtime Pharmaceutical Co., Ltd. |
Bispecific antibody targeting cd3 and bcma, and uses thereof
|
SG11202102859TA
(en)
|
2018-12-21 |
2021-04-29 |
Hoffmann La Roche |
Antibodies binding to cd3
|
KR102524247B1
(ko)
*
|
2018-12-21 |
2023-04-21 |
가톨릭대학교 산학협력단 |
p40-EBI3의 복합체 및 이의 용도
|
KR20210107057A
(ko)
|
2018-12-21 |
2021-08-31 |
제넨테크, 인크. |
핵산의 표적화 통합
|
JP2022521750A
(ja)
|
2019-02-21 |
2022-04-12 |
マレンゴ・セラピューティクス,インコーポレーテッド |
カルレティキュリンに結合する多機能性分子およびその使用
|
CN114127111A
(zh)
|
2019-02-21 |
2022-03-01 |
马伦戈治疗公司 |
与nkp30结合的抗体分子及其用途
|
AU2020226904A1
(en)
|
2019-02-21 |
2021-09-16 |
Marengo Therapeutics, Inc. |
Anti-TCR antibody molecules and uses thereof
|
WO2020172571A1
(en)
|
2019-02-21 |
2020-08-27 |
Elstar Therapeutics, Inc. |
Multifunctional molecules that bind to t cell related cancer cells and uses thereof
|
AU2020224680A1
(en)
|
2019-02-21 |
2021-09-16 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to T cells and uses thereof to treat autoimmune disorders
|
KR20210143192A
(ko)
|
2019-02-22 |
2021-11-26 |
우한 이지 바이오파마 씨오., 엘티디. |
변형된 Fc 단편, 이를 포함하는 항체 및 이의 응용
|
AU2020232605A1
(en)
|
2019-03-01 |
2021-10-21 |
Xencor, Inc. |
Heterodimeric antibodies that bind ENPP3 and CD3
|
PE20220763A1
(es)
*
|
2019-05-08 |
2022-05-16 |
Janssen Biotech Inc |
Materiales y metodos para modular la inmunidad mediada por celulas t
|
US20200392229A1
(en)
|
2019-06-11 |
2020-12-17 |
Alector Llc |
Methods of use of anti-sortilin antibodies
|
JP2022537650A
(ja)
|
2019-06-13 |
2022-08-29 |
アムジエン・インコーポレーテツド |
生物製剤の製造における自動化された生物量に基づく灌流制御
|
CN116987197A
(zh)
*
|
2019-06-20 |
2023-11-03 |
成都恩沐生物科技有限公司 |
共价多特异性抗体
|
CR20220049A
(es)
*
|
2019-07-10 |
2022-03-02 |
Chugai Pharmaceutical Co Ltd |
Moléculas de unión a claudina-6 y usos de las mismas
|
BR112022001460A2
(pt)
|
2019-07-31 |
2022-03-22 |
Hoffmann La Roche |
Moléculas de ligação ao antígeno biespecíficas, um ou mais polinucleotídeos isolados, célula hospedeira, método para produzir uma molécula de ligação ao antígeno biespecífica e para tratar uma doença em um indivíduo, composição farmacêutica, uso da molécula de ligação ao antígeno biespecífica e invenção
|
US11667699B2
(en)
|
2019-07-31 |
2023-06-06 |
Alector Llc |
Anti-MS4A4A antibodies and methods of use thereof
|
JP2022543551A
(ja)
|
2019-07-31 |
2022-10-13 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
Gprc5dに結合する抗体
|
CN112390882A
(zh)
*
|
2019-08-19 |
2021-02-23 |
杨洋 |
靶向cd3和cd20的双特异性抗体及其应用
|
WO2021050640A1
(en)
|
2019-09-10 |
2021-03-18 |
Amgen Inc. |
Purification method for bispecific antigen-binding polypeptides with enhanced protein l capture dynamic binding capacity
|
EP4031579A2
(en)
|
2019-09-18 |
2022-07-27 |
F. Hoffmann-La Roche AG |
Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use
|
EP3819007A1
(en)
|
2019-11-11 |
2021-05-12 |
Amgen Research (Munich) GmbH |
Dosing regimen for anti-bcma agents
|
EP4058485A1
(en)
|
2019-11-13 |
2022-09-21 |
Amgen Inc. |
Method for reduced aggregate formation in downstream processing of bispecific antigen-binding molecules
|
CA3161390A1
(en)
|
2019-12-18 |
2021-06-24 |
Tina WEINZIERL |
Antibodies binding to hla-a2/mage-a4
|
UY38995A
(es)
|
2019-12-20 |
2021-06-30 |
Amgen Inc |
Constructos de anticuerpo multiespecíficos agonistas de cd40 dirigidos a mesotelina para el tratamiento de tumores sólidos
|
KR20220118527A
(ko)
|
2019-12-23 |
2022-08-25 |
제넨테크, 인크. |
아포지질단백질 l1-특이적 항체 및 이용 방법
|
EP4084821A4
(en)
|
2020-01-03 |
2024-04-24 |
Marengo Therapeutics Inc |
CD33-BINDING MULTIFUNCTIONAL MOLECULES AND THEIR USES
|
WO2021150824A1
(en)
|
2020-01-22 |
2021-07-29 |
Amgen Research (Munich) Gmbh |
Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof
|
CA3174103A1
(en)
|
2020-03-06 |
2021-09-10 |
Go Therapeutics, Inc. |
Anti-glyco-cd44 antibodies and their uses
|
US20230146593A1
(en)
|
2020-03-12 |
2023-05-11 |
Amgen Inc. |
Method for treatment and prophylaxis of crs in patients comprising a combination of bispecific antibodies binding to cds x cancer cell and tnf alpha or il-6 inhibitor
|
AU2021240028A1
(en)
|
2020-03-19 |
2022-09-15 |
Amgen Inc. |
Antibodies against mucin 17 and uses thereof
|
CN115315512A
(zh)
|
2020-03-26 |
2022-11-08 |
基因泰克公司 |
具有降低的宿主细胞蛋白质的经修饰的哺乳动物细胞
|
WO2021200898A1
(en)
|
2020-03-31 |
2021-10-07 |
Chugai Seiyaku Kabushiki Kaisha |
Dll3-targeting multispecific antigen-binding molecules and uses thereof
|
CA3178472A1
(en)
|
2020-04-24 |
2021-10-28 |
F. Hoffmann-La Roche Ag |
Enzyme and pathway modulation with sulfhydryl compounds and their derivatives
|
JP2023523011A
(ja)
|
2020-04-24 |
2023-06-01 |
マレンゴ・セラピューティクス,インコーポレーテッド |
T細胞関連のがん細胞に結合する多機能性分子およびその使用
|
US11919956B2
(en)
|
2020-05-14 |
2024-03-05 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
|
TW202210101A
(zh)
|
2020-05-29 |
2022-03-16 |
美商安進公司 |
與cd33和cd3結合的雙特異性構建體的減輕不良反應投與
|
TW202204396A
(zh)
|
2020-06-08 |
2022-02-01 |
瑞士商赫孚孟拉羅股份公司 |
抗hbv抗體及使用方法
|
WO2021255146A1
(en)
|
2020-06-19 |
2021-12-23 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3 and cea
|
WO2021255155A1
(en)
|
2020-06-19 |
2021-12-23 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3 and cd19
|
TW202216767A
(zh)
|
2020-06-19 |
2022-05-01 |
瑞士商赫孚孟拉羅股份公司 |
與CD3及FolR1結合之抗體
|
CR20220628A
(es)
|
2020-06-19 |
2023-01-24 |
Hoffmann La Roche |
Anticuerpos que se unen a cd3
|
EP4168124A2
(en)
*
|
2020-06-23 |
2023-04-26 |
Kadmon Corporation, LLC |
Anti-pd-1 antibodies and fusion proteins
|
WO2021262783A1
(en)
|
2020-06-24 |
2021-12-30 |
Genentech, Inc. |
Apoptosis resistant cell lines
|
IL299120A
(en)
|
2020-06-24 |
2023-02-01 |
Genentech Inc |
A targeted combination of nucleic acids
|
AR123001A1
(es)
|
2020-07-17 |
2022-10-19 |
Genentech Inc |
Anticuerpos anti-notch2 y métodos de uso
|
WO2022040482A1
(en)
|
2020-08-19 |
2022-02-24 |
Xencor, Inc. |
Anti-cd28 and/or anti-b7h3 compositions
|
AU2021331075A1
(en)
|
2020-08-26 |
2023-04-06 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
KR20230074487A
(ko)
|
2020-08-26 |
2023-05-30 |
마렝고 테라퓨틱스, 인크. |
Trbc1 또는 trbc2를 검출하는 방법
|
EP4204096A2
(en)
|
2020-08-26 |
2023-07-05 |
Marengo Therapeutics, Inc. |
Antibody molecules that bind to nkp30 and uses thereof
|
CN116648507A
(zh)
|
2020-08-28 |
2023-08-25 |
基因泰克公司 |
宿主细胞蛋白的CRISPR/Cas9多重敲除
|
MX2023002545A
(es)
|
2020-09-10 |
2023-03-14 |
Genmab As |
Anticuerpo biespecifico contra cumulo de diferenciacion 3 (cd3) y cumulo de diferenciacion 20 (cd20) en terapia de combinacion para el tratamiento de linfoma difuso de celulas b grandes.
|
CN116437956A
(zh)
|
2020-09-10 |
2023-07-14 |
健玛保 |
用于治疗慢性淋巴细胞白血病的针对cd3和cd20的双特异性抗体
|
IL301102A
(en)
|
2020-09-10 |
2023-05-01 |
Genmab As |
A bispecific antibody against CD3 and CD20 in combination therapy for the treatment of diffuse large B-cell lymphoma
|
KR20230066391A
(ko)
|
2020-09-10 |
2023-05-15 |
젠맵 에이/에스 |
여포성 림프종을 치료하기 위한 조합 요법에서의 cd3 및 cd20에 대한 이중특이적 항체
|
JP2023542289A
(ja)
|
2020-09-10 |
2023-10-06 |
ジェンマブ エー/エス |
濾胞性リンパ腫を治療するための併用療法におけるcd3及びcd20に対する二重特異性抗体
|
JP2023547520A
(ja)
|
2020-11-05 |
2023-11-10 |
メンドゥス・ベスローテン・フェンノートシャップ |
免疫療法における腫瘍非依存性抗原の使用
|
EP4240770A1
(en)
|
2020-11-06 |
2023-09-13 |
Amgen Research (Munich) GmbH |
Polypeptide constructs selectively binding to cldn6 and cd3
|
CA3200317A1
(en)
|
2020-11-06 |
2022-05-12 |
Amgen Inc. |
Multitargeting bispecific antigen-binding molecules of increased selectivity
|
KR20230098335A
(ko)
|
2020-11-06 |
2023-07-03 |
암젠 인크 |
클리핑 비율이 감소된 항원 결합 도메인
|
EP4240767A1
(en)
|
2020-11-06 |
2023-09-13 |
Amgen Inc. |
Polypeptide constructs binding to cd3
|
TW202233682A
(zh)
|
2020-11-10 |
2022-09-01 |
美商安進公司 |
用於投與BCMAxCD3結合分子之方法
|
AU2021392039A1
(en)
|
2020-12-02 |
2023-06-29 |
Alector Llc |
Methods of use of anti-sortilin antibodies
|
KR20230120665A
(ko)
|
2020-12-17 |
2023-08-17 |
에프. 호프만-라 로슈 아게 |
항-hla-g 항체 및 이의 용도
|
WO2022169872A1
(en)
|
2021-02-03 |
2022-08-11 |
Genentech, Inc. |
Multispecific binding protein degrader platform and methods of use
|
WO2022169825A1
(en)
|
2021-02-03 |
2022-08-11 |
Mozart Therapeutics, Inc. |
Binding agents and methods of using the same
|
JP2024512324A
(ja)
|
2021-03-05 |
2024-03-19 |
ジーオー セラピューティクス,インコーポレイテッド |
抗グリコcd44抗体およびその使用
|
US11739144B2
(en)
|
2021-03-09 |
2023-08-29 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and CLDN6
|
KR20230154311A
(ko)
|
2021-03-10 |
2023-11-07 |
젠코어 인코포레이티드 |
Cd3 및 gpc3에 결합하는 이종이량체 항체
|
JP2024512377A
(ja)
|
2021-03-12 |
2024-03-19 |
ジェネンテック, インコーポレイテッド |
抗klk7抗体、抗klk5抗体、多重特異性抗klk5/klk7抗体、及び使用方法
|
CN116981696A
(zh)
|
2021-03-18 |
2023-10-31 |
艾莱克特有限责任公司 |
抗tmem106b抗体及其使用方法
|
JP2024511610A
(ja)
|
2021-03-23 |
2024-03-14 |
アレクトル エルエルシー |
コロナウイルス感染の治療及び予防のための抗tmem106b抗体
|
EP4314078A1
(en)
|
2021-04-02 |
2024-02-07 |
Amgen Inc. |
Mageb2 binding constructs
|
WO2022216993A2
(en)
|
2021-04-08 |
2022-10-13 |
Marengo Therapeutics, Inc. |
Multifuntional molecules binding to tcr and uses thereof
|
EP4319820A1
(en)
|
2021-04-10 |
2024-02-14 |
Profoundbio Us Co. |
Folr1 binding agents, conjugates thereof and methods of using the same
|
JP2024514222A
(ja)
|
2021-04-19 |
2024-03-28 |
ジェネンテック, インコーポレイテッド |
改変された哺乳動物細胞
|
CN117203238A
(zh)
|
2021-04-23 |
2023-12-08 |
普方生物制药美国公司 |
Cd70结合剂、其偶联物及其使用方法
|
AU2022269312A1
(en)
|
2021-05-06 |
2023-10-19 |
Amgen Research (Munich) Gmbh |
Cd20 and cd22 targeting antigen-binding molecules for use in proliferative diseases
|
CN117396599A
(zh)
|
2021-05-21 |
2024-01-12 |
基因泰克公司 |
用于生产目的重组产物的经修饰的细胞
|
WO2023287663A1
(en)
|
2021-07-13 |
2023-01-19 |
Genentech, Inc. |
Multi-variate model for predicting cytokine release syndrome
|
CN117730102A
(zh)
|
2021-07-22 |
2024-03-19 |
豪夫迈·罗氏有限公司 |
异二聚体Fc结构域抗体
|
CN117794953A
(zh)
|
2021-08-03 |
2024-03-29 |
豪夫迈·罗氏有限公司 |
双特异性抗体及使用方法
|
AU2022324456A1
(en)
|
2021-08-05 |
2024-02-15 |
Go Therapeutics, Inc. |
Anti-glyco-muc4 antibodies and their uses
|
WO2023034571A1
(en)
|
2021-09-03 |
2023-03-09 |
Go Therapeutics, Inc. |
Anti-glyco-lamp1 antibodies and their uses
|
TW202328188A
(zh)
|
2021-09-03 |
2023-07-16 |
美商Go治療公司 |
抗醣化-cmet抗體及其用途
|
WO2023076876A1
(en)
|
2021-10-26 |
2023-05-04 |
Mozart Therapeutics, Inc. |
Modulation of immune responses to viral vectors
|
WO2023078968A1
(en)
|
2021-11-03 |
2023-05-11 |
Affimed Gmbh |
Bispecific cd16a binders
|
WO2023079493A1
(en)
|
2021-11-03 |
2023-05-11 |
Affimed Gmbh |
Bispecific cd16a binders
|
AR127887A1
(es)
|
2021-12-10 |
2024-03-06 |
Hoffmann La Roche |
Anticuerpos que se unen a cd3 y plap
|
TW202340251A
(zh)
|
2022-01-19 |
2023-10-16 |
美商建南德克公司 |
抗notch2抗體及結合物及其使用方法
|
TW202346368A
(zh)
|
2022-05-12 |
2023-12-01 |
德商安美基研究(慕尼黑)公司 |
具有增加的選擇性的多鏈多靶向性雙特異性抗原結合分子
|
WO2024020564A1
(en)
|
2022-07-22 |
2024-01-25 |
Genentech, Inc. |
Anti-steap1 antigen-binding molecules and uses thereof
|
WO2024030956A2
(en)
|
2022-08-03 |
2024-02-08 |
Mozart Therapeutics, Inc. |
Cd39-specific binding agents and methods of using the same
|
WO2024059675A2
(en)
|
2022-09-14 |
2024-03-21 |
Amgen Inc. |
Bispecific molecule stabilizing composition
|